Catalyst
Slingshot members are tracking this event:
Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
REPH |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 27, 2016
Related Projects
- With another successful trial for Meloxicam in post operative pain, where could the drug fit into the treatment landscape? REPH, INSY Executed On: Dec 02, 2016 at 10:30 AM EST
Related Keywords
Pivotal Phase 3 Trial, Iv Meloxicam, Acute Postoperative Pain